Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Inferior survival in black AML patients treated with intensive chemotherapy in ECOG-ACRIN clinical trials is independent of cytogenetic profiles

View Full Paper
Ask AI
Bookmark
Share

Authors

SFShella Saint Fleur-LominyZSZhuoxin SunFGFrancine E. Garrett-Bakelman

Discussion

Loading...

Member takes

Overview

Observational analysis finds inferior survival outcomes in Black AML patients, suggesting disparities in treatment and genomic profiles.

Key Points

  • Survival outcomes were inferior in Black AML patients, highlighting systemic disparities in treatment response.
  • Key evidence shows Black race was an independent factor for poorer overall and disease-free survival rates.
  • Observational analysis across clinical trials reveals no significant racial differences in specific cytogenetic profiles.
  • The findings stress the need for addressing treatment access gaps, particularly in stem cell transplants for marginalized populations.

Cite This Study

Fleur-Lominy et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d706https://doi.org/10.1182/blood-2025-290
View Full Paper
Ask AI
Bookmark
Share